checkAd
    VYNE Therapeutics Registered (Old) Aktie
    2,2000
     
    EUR
    +1,85 %
    +0,0400 EUR
    Letzter Kurs 12.02.21 Tradegate
    2,1000
     
    EUR
    1.905 STK
    Geldkurs 15.02.21
    2,2400
     
    EUR
    1.759 STK
    Briefkurs 15.02.21
    ISIN: US92941V1008 · WKN: A2QCQ8 · USA

    Neueste Nachrichten

    VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
    19.03.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
    29.02.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
    27.02.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
    21.02.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
    10.01.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
    03.01.24 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
    13.11.23 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
    07.11.23 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
    01.11.23 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
    30.10.23 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Announces Private Placement of $88 Million
    30.10.23 · globenewswire · VYNE Therapeutics Registered (Old)
    VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
    30.10.23 · globenewswire · VYNE Therapeutics Registered (Old)